April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
A Comparison of the in-vitro Susceptibility Profile of Ceftobiprole Against Methicillin Resistant Staphylococcus aureus (MRSA) Ocular Isolates
Author Affiliations & Notes
  • R. P. Conley
    Ophthalmology,
    New York Eye and Ear Infirmary, New York, New York
  • M. K. Shah
    Pathology and Laboratory Medicine,
    New York Eye and Ear Infirmary, New York, New York
  • G. Thompson
    Ophthalmology,
    New York Eye and Ear Infirmary, New York, New York
  • W. Perez
    Pathology and Laboratory Medicine,
    New York Eye and Ear Infirmary, New York, New York
  • J. A. Seedor
    Ophthalmology,
    New York Eye and Ear Infirmary, New York, New York
  • D. C. Ritterband
    Ophthalmology,
    New York Eye and Ear Infirmary, New York, New York
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5711. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. P. Conley, M. K. Shah, G. Thompson, W. Perez, J. A. Seedor, D. C. Ritterband; A Comparison of the in-vitro Susceptibility Profile of Ceftobiprole Against Methicillin Resistant Staphylococcus aureus (MRSA) Ocular Isolates. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5711.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To study the in-vitro susceptibility profiles of ceftobiprole, a novel 5th generation cephalosporin against ocular isolates of Methicillin Resistant Staph aureus (MRSA).

Methods: : 15 MRSA, 3 Methicillin Sensitive Staph aureus (MSSA), 3 Staph epidermidis, 1 Strep viridans group, and 1 each of Serratia marcescens, Haemophilus influenzae, and Pseudomonas aeruginosa isolates from cases of corneal ulcers were tested for in vitro susceptibility against ceftobiprole, moxifloxacin, gatifloxacin, gentamicin, and vancomycin using a Kirby Bauer method.

Results: : Ceftobiprole was active against all 15 MRSA strains tested with zones of inhibition ranging from (18 to 38 mm). Moxifloxacin and Gatifloxacin had 8/15 resistant and 10/15 resistant MRSA strains respectively. Gentamicin had 3/15 resistant MRSA organisms. All 15 MRSA strains were sensitive to vancomycin. In addition ceftobiprole was active against all the other isolates.

Conclusions: : Ceftobiprole is the first of a new class of broad-spectrum anti-MSRA cephalosporins with activity against methicillin-resistant Staphylococcus aureus and gram negative organisms. With increasing concern of resistance among MRSA ocular isolates to currently available antimicrobials ceftobiprole may be a promising new therapeutic alternative.

Keywords: antibiotics/antifungals/antiparasitics • clinical laboratory testing • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×